ROCTAVIAN

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
II/0008/G	This was an application for a group of variations. Grouped application comprising two variations as follows: C.I.4 - Update of section 4.5 of the SmPC in order to add drug-drug interaction information with Isotretinoin and Efavirenz based on results from study "In vitro Drug-Drug Interaction Study: Effects	09/11/2023		SmPC	SmPC section 4.5 new text: Isotretinoin (…) An in vitro study in human primary hepatocytes indicated that isotretinoin suppressed factor VIII expression independent of hepatotoxicity. Isotretinoin is not recommended in patients who are benefiting from valoctocogene roxaparvovec.

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

	of Concomitant Administration of Isotretinoin, Amphetamine, Omeprazole, Celecoxib and Selected HAART Medications with AAV5-FVIII-SQ on Cytotoxicity and AAV5-FVIII-SQ DNA and RNA Expression in Primary Human Hepatocytes". A.6 - To change the ATC Code from B02BD1 to "not yet assigned". C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data A.6 - Administrative change - Change in ATC Code/ATC Vet Code				Efavirenz An in vitro study in human primary hepatocytes indicated that efavirenz suppressed factor VIII expression independent of hepatotoxicity. Efavirenz is not recommended in patients who are benefiting from valoctocogene roxaparvovec. The use of non efavirenz treatments should be considered. For more information, please refer to the Summary of Product Characteristics.
PSUSA/11009 /202302	Periodic Safety Update EU Single assessment - valoctocogene roxaparvovec	28/09/2023	n/a		PRAC Recommendation - maintenance
IB/0007	B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol	08/09/2023		SmPC	
IB/0006	B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS	23/08/2023	n/a		
R/0003	Renewal of the marketing authorisation.	25/05/2023	24/07/2023	SmPC	The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the

					opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for ROCTAVIAN, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion.
II/0004/G	This was an application for a group of variations. B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method	26/04/2023	n/a		
IB/0002	B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol	09/11/2022	24/07/2023	SmPC, Labelling and PL	
IB/0001	B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place	27/10/2022	n/a		